Heart Failure NYHA Class II

Cardiovascular
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
Early Metabolic Adaptations to SGLT2 Inhibition in Heart FailureN/A1 trial
Active Trials
NCT05885607Enrolling By Invitation40Est. Mar 2026
Rhythm Pharmaceuticals
1 program
Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware downloadN/A1 trial
Active Trials
NCT04452149Completed826Est. Jun 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AmgenEarly Metabolic Adaptations to SGLT2 Inhibition in Heart Failure
Rhythm PharmaceuticalsReveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download

Clinical Trials (2)

Total enrollment: 866 patients across 2 trials

NCT05885607AmgenEarly Metabolic Adaptations to SGLT2 Inhibition in Heart Failure

Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure

Start: Jun 2023Est. completion: Mar 202640 patients
N/AEnrolling By Invitation
NCT04452149Rhythm PharmaceuticalsReveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download

Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure

Start: Sep 2020Est. completion: Jun 2025826 patients
N/ACompleted

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space